Using fecal microbiota transplantation to treat irritable bowel syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness and safety of fecal microbiota transplantation (FMT) as a treatment for patients with irritable bowel syndrome (IBS). The study involves infusing a fecal suspension from healthy donors into the patients' colons to restore a balanced gut microbiome. Participants will receive FMT at least twice and will be monitored for a minimum of six months using questionnaires to assess their symptoms and overall gut health. The trial is conducted at Guangzhou First People's Hospital, focusing on a standardized approach to microbiota isolation and transplantation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

To be considered eligible for enrolment into the study, subjects must:

* Be able to give written informed consent.
* Males and females aged \>18 and \<75
* Have IBS as defined by the Rome IV criteria

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the below criteria:

* pregnant or having a follow-up of less than 6 months;
* unable to give informed consent;
* suffering from other severe disease ,including liver and kidney failure, cancers, intestinal diseases, inflammatory bowel disease, C difficile infection;
* unable to undergo endoscopy.

Where it's running

• Guangzhou First People's Hospital
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Hongli Huang, MM — Guangzhou First People's Hospital
• Study coordinator: Hongli Huang, MM
• Email: honglisums@126.com
• Phone: 86-13631316718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity

  This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.

  Recruiting at 2 sites University of Palermo · Palermo, Palermo and 1 other locations · NCT07750535

• Fecal transplant plus standard therapy for refractory hepatic encephalopathy after TIPS

  This study tests whether adding fecal microbiota transplantation to usual medicines helps people with recurrent hepatic encephalopathy after TIPS implant.

  Recruiting Early Phase 1 Air Force Military Medical University, China · Xi'an · NCT07683936

• Repeated transcranial magnetic stimulation to treat diarrhea-predominant irritable bowel syndrome

  This study will test whether repeated transcranial magnetic stimulation (rTMS) can reduce diarrhea, abdominal pain, and improve quality of life in adults with IBS-D.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07581756

• Brenipatide (LY3537031) for IBS with constipation

  This trial will test whether brenipatide (LY3537031), given by a small under-the-skin injection, helps adults with IBS-C have less belly pain and more normal bowel movements compared with a placebo.

  Recruiting at 64 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 69 other locations · NCT07545772

• Brenipatide (LY3537031) treatment for adults with IBS‑D

  This will test whether brenipatide (LY3537031) given under the skin helps adults with IBS‑D reduce belly pain and improve stool consistency compared with placebo.

  Recruiting at 80 sites Phase 2 Eli Lilly and Company · Mesa, Arizona and 88 other locations · NCT07545759

• Camlipixant for IBS-D and IBS-M: a test in adults

  This study tests camlipixant versus placebo in adults with IBS with diarrhea or mixed IBS to see if it helps reduce symptoms and is safe.

  Recruiting at 114 sites Phase 2 GlaxoSmithKline · Anniston, Alabama and 113 other locations · NCT07519395

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.